U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07447102) titled 'Phase II Clinical Study of BC006 in Patients With Idiopathic Pulmonary Fibrosis' on Feb. 24.
Brief Summary: This is a multicenter, Phase II clinical study to evaluate the efficacy and safety of BC006 over a 24-week treatment period in patients with idiopathic pulmonary fibrosis (IPF). The study consists of two phases: an open-label safety run-in phase and a double-blind, randomized, placebo-controlled phase.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Idiopathic Pulmonary Fibrosis (IPF)
Intervention:
DRUG: BC006
A 1.0 mg/kg or 0.3 mg/kg IV infusion of BC006 based on the patients weight will be administere...